Select Publications

Vaxiion's 2023 publication in The Journal for ImmunoTherapy of Cancer

Key highlights:

VAX014 elicits tumor-specific T cell-mediated immune clearance of injected and in non-injected tumors

VAX014 activates multiple innate immune pathways leading to T cell priming

Strong synergy with systemic immune checkpoint blockade

Vaxiion's 2022 publication in Cancer Immunology Research

Key highlights:

VAX014 elicits tumor-specific T cell-mediated immune clearance of orthotopic bladder tumors

VAX014 acts through in situ immunization

Strong synergy with systemic PD-(L)1 systemic immune checkpoint blockade

Vaxiion's 2016 publication in Molecular Therapy - Oncolytics

Key highlights:

First publication characterizing details of the structure, integrin-specificity, and oncolytic mechanism of action of VAX014 (preclincial name VAX-IP)

Preliminary efficacy data in two murine models of non-muscle invasive bladder cancer

Established dose level(s) and dosing frequency

Other Publications

Click to read

VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.